1 / 8

Financial Analysis

This report provides a comprehensive financial analysis of Mylan's growth drivers, focusing on global sales growth and product expansion strategies. It highlights key regions such as EMEA, APAC, and North America, detailing the introduction of 500 new products by 2013, including EpiPen and COPD treatments. Additionally, it analyzes Mylan's financial structure, including cash flow dynamics and debt-equity ratio, while addressing risks and opportunities from emerging markets such as India and China. The operating margin will be highlighted as a key driver for shareholder value.

lesley
Télécharger la présentation

Financial Analysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Financial Analysis • Growth Drivers • Global Sales Growth • Product Growth • Structure • Increase of Cash Flow • Risky structure

  2. Global Sales Growth • EMEA • Expansion on generic utilization • 360 New Products • APAC • Expansion of Products • 50 New Products • Japan well positioned for future growth • India and China-Emerging Market expansion • North America • Expansion of Products • 90 New Products • 500 New Products through year 2013

  3. Product Growth • EpiPen Auto-Injector • Expansion in Markets (Europe) • Three 10% price increases • COPD Treatment • Introduction of products • Launch for 2015 • Potential for $500 million peak sales • Biogenerics • Launch in US 2014 • Launch in less regulated Markets 2013 • Generic Copanxone • Expansion into Emerging Markets

  4. Mylan’s Financial Structure • Risky • Cash Coverage Ratio • Low from 2010 to 2014 • Financially risky • Debt Equity Ratio • More debt then equity • Compared to industry ranked 11 • Cash Flow • Increase with product and market expansion • OCF increase from 2011 to 2013 • Reduce debt and create more value.

  5. Generic Investor’s Valuation • DCF vs. Economic Profit • Expected Value Analysis • Key Driver Operating Margin

  6. DCF vs. Economic Profit

  7. Expected Value Analysis • Key Driver • Operating Margin

  8. Why Operating Margin? • Largest affect on value • Factors that impact OM • Increase Unit Price of Product • Expand Product Line • Expand Geographical Reach • Equity Value Increase to $26.48

More Related